Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover weight loss drugs like Wegovy and Ozempic. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.